Is It Time To Reconsider Iovance Biotherapeutics (IOVA) After Prolonged Share Price Weakness
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
-
If you are wondering whether Iovance Biotherapeutics is a bargain or a value trap at around US$2.53 per share, you are not alone.
-
The stock has seen a 0.8% decline over the last week, an 8.7% decline over the last 30 days, and is roughly flat year to date at a 0.4% gain, while the 1 year and 3 year returns of 55.5% and 65.6% declines highlight how sentiment has shifted over time.
-
That kind of long term share price pressure often reflects changing views on funding needs, clinical milestones, or regulatory progress. These factors can set expectations low and make future news more impactful….
